301 related articles for article (PubMed ID: 28405618)
1. Efficacy of ALK5 inhibition in myelofibrosis.
Yue L; Bartenstein M; Zhao W; Ho WT; Han Y; Murdun C; Mailloux AW; Zhang L; Wang X; Budhathoki A; Pradhan K; Rapaport F; Wang H; Shao Z; Ren X; Steidl U; Levine RL; Zhao ZJ; Verma A; Epling-Burnette PK
JCI Insight; 2017 Apr; 2(7):e90932. PubMed ID: 28405618
[TBL] [Abstract][Full Text] [Related]
2. Hmga2 promotes the development of myelofibrosis in Jak2
Dutta A; Hutchison RE; Mohi G
Blood; 2017 Aug; 130(7):920-932. PubMed ID: 28637665
[TBL] [Abstract][Full Text] [Related]
3. TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis.
Varricchio L; Iancu-Rubin C; Upadhyaya B; Zingariello M; Martelli F; Verachi P; Clementelli C; Denis JF; Rahman AH; Tremblay G; Mascarenhas J; Mesa RA; O'Connor-McCourt M; Migliaccio AR; Hoffman R
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34383713
[TBL] [Abstract][Full Text] [Related]
4. Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice.
Ozono Y; Shide K; Kameda T; Kamiunten A; Tahira Y; Sekine M; Akizuki K; Nakamura K; Iwakiri H; Sueta M; Hidaka T; Kubuki Y; Yamamoto S; Hasuike S; Sawaguchi A; Nagata K; Shimoda K
Leukemia; 2021 Feb; 35(2):454-467. PubMed ID: 32472085
[TBL] [Abstract][Full Text] [Related]
5. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
6. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
[TBL] [Abstract][Full Text] [Related]
7. Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis.
Maekawa T; Osawa Y; Izumi T; Nagao S; Takano K; Okada Y; Tachi N; Teramoto M; Kawamura T; Horiuchi T; Saga R; Kato S; Yamamura T; Watanabe J; Kobayashi A; Kobayashi S; Sato K; Hashimoto M; Suzu S; Kimura F
Leukemia; 2017 Dec; 31(12):2709-2716. PubMed ID: 28386106
[TBL] [Abstract][Full Text] [Related]
8. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
Rambaldi B; Diral E; Donsante S; Di Marzo N; Mottadelli F; Cardinale L; Dander E; Isimbaldi G; Pioltelli P; Biondi A; Riminucci M; D'Amico G; Elli EM; Pievani A; Serafini M
Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
[TBL] [Abstract][Full Text] [Related]
10. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.
Kirabo A; Park SO; Wamsley HL; Gali M; Baskin R; Reinhard MK; Zhao ZJ; Bisht KS; Keserű GM; Cogle CR; Sayeski PP
Am J Pathol; 2012 Sep; 181(3):858-65. PubMed ID: 22796437
[TBL] [Abstract][Full Text] [Related]
11. CAMK2G is identified as a novel therapeutic target for myelofibrosis.
Miyauchi M; Sasaki K; Kagoya Y; Taoka K; Masamoto Y; Yamazaki S; Arai S; Mizuno H; Kurokawa M
Blood Adv; 2022 Mar; 6(5):1585-1597. PubMed ID: 34521112
[TBL] [Abstract][Full Text] [Related]
12. LY2109761 reduces TGF-β1-induced collagen production and contraction in hypertrophic scar fibroblasts.
Wei G; Xu Q; Liu L; Zhang H; Tan X; Zhang C; Han C; Guo Y; Han G; Zhang C
Arch Dermatol Res; 2018 Oct; 310(8):615-623. PubMed ID: 30046895
[TBL] [Abstract][Full Text] [Related]
13. A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells.
Wang X; Haylock D; Hu CS; Kowalczyk W; Jiang T; Qiu J; Mosoyan G; He W; Marshall N; Mascarenhas J; Tarasova A; Brody J; Winkler D; Hoffman R
Blood; 2016 Jun; 127(26):3398-409. PubMed ID: 27114459
[TBL] [Abstract][Full Text] [Related]
14. JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation.
Besancenot R; Roos-Weil D; Tonetti C; Abdelouahab H; Lacout C; Pasquier F; Willekens C; Rameau P; Lecluse Y; Micol JB; Constantinescu SN; Vainchenker W; Solary E; Giraudier S
Blood; 2014 Sep; 124(13):2104-15. PubMed ID: 25143485
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.
Koppikar P; Abdel-Wahab O; Hedvat C; Marubayashi S; Patel J; Goel A; Kucine N; Gardner JR; Combs AP; Vaddi K; Haley PJ; Burn TC; Rupar M; Bromberg JF; Heaney ML; de Stanchina E; Fridman JS; Levine RL
Blood; 2010 Apr; 115(14):2919-27. PubMed ID: 20154217
[TBL] [Abstract][Full Text] [Related]
16. Role of ALK5/Smad2/3 and MEK1/ERK Signaling in Transforming Growth Factor Beta 1-modulated Growth, Collagen Turnover, and Differentiation of Stem Cells from Apical Papilla of Human Tooth.
Chang HH; Chang MC; Wu IH; Huang GF; Huang WL; Wang YL; Lee SY; Yeh CY; Guo MK; Chan CP; Hsien HC; Jeng JH
J Endod; 2015 Aug; 41(8):1272-80. PubMed ID: 26001858
[TBL] [Abstract][Full Text] [Related]
17. JAK2V617F Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion in Mice Through Thrombopoietin/MPL Signaling.
Zhang Y; Lin CHS; Kaushansky K; Zhan H
Stem Cells; 2018 Nov; 36(11):1676-1684. PubMed ID: 30005133
[TBL] [Abstract][Full Text] [Related]
18. Ligand-independent thrombopoietin mutant receptor requires cell surface localization for endogenous activity.
Marty C; Chaligné R; Lacout C; Constantinescu SN; Vainchenker W; Villeval JL
J Biol Chem; 2009 May; 284(18):11781-91. PubMed ID: 19261614
[TBL] [Abstract][Full Text] [Related]
19. Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis.
Rossi C; Zini R; Rontauroli S; Ruberti S; Prudente Z; Barbieri G; Bianchi E; Salati S; Genovese E; Bartalucci N; Guglielmelli P; Tagliafico E; Rosti V; Barosi G; Vannucchi AM; Manfredini R;
Mol Oncol; 2018 Dec; 12(12):2102-2123. PubMed ID: 30259659
[TBL] [Abstract][Full Text] [Related]
20. Involvement of TGFβ1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosis.
Badalucco S; Di Buduo CA; Campanelli R; Pallotta I; Catarsi P; Rosti V; Kaplan DL; Barosi G; Massa M; Balduini A
Haematologica; 2013 Apr; 98(4):514-7. PubMed ID: 23403314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
